Global In Vitro Diagnostics Market Size, Share, Opportunities, And Trends By Technique (Immunoassay, Molecular Diagnostics, Haematology, Other), By Application (Infectious Diseases, Autoimmune Diseases, Drug Testing, Oncology, Others), By End-User (Diagnostic Laboratories, Hospitals And Clinics, Research Laboratories And Institutes), And By Geography - Forecasts From 2025 To 2030

In Vitro Diagnostics Market Size:

The in-vitro diagnostics market is anticipated to expand at a CAGR of 5.87% throughout the forecast period, from US$109.480 billion in 2025 to a total market value of US$145.459 billion in 2030.

In Vitro Diagnostics Market Trends:

The in vitro diagnostic (IVD) market growth is ascribed to various components, like the rising prevalence of infectious and persistent ailments. Rising utilization of point-of-care diagnostics and inventive technological progressions related to in-vitro diagnostics product profiles will surge market growth. Rising awareness among the general population for disease prevention and the adoption of personalized medications and treatment procedures will expand the industry in the coming years.

Additionally, with the rapid increase in cancer cases, there will be a rise in the requirement for symptomatic and diagnostic courses for detecting and preventing cancer at an early stage, which can develop the in vitro diagnostics industry in the forecasted period. World Health Organization reported in February 2024 that the number of new cancer cases was 20 million in 2022 worldwide and is predicted to rise by 77% by 2025, with more than 35 million new cases to be recorded. This expansion is credited to population aging, population rise, and changes in exposure to risk variables, such as tobacco, alcohol, air pollution, and obesity.

In-Vitro Diagnostics Market Growth Drivers:

• The increased prevalence of chronic and infectious diseases, as well as an aging population, is expected to boost the market expansion.

The increasing geriatric population in developed and developing countries would positively contribute to the IVD market. The predominance of age-related disorders is anticipated to rise significantly as the world's aging population develops quickly. The aging population is increasing and growing in other industrialized economies globally. Japan, for instance, has the most elevated proportion of the elderly population to the productive population, followed by Germany. The American Medical Association reported that by 2030, it is anticipated that 60% of individuals aged 65 and over will have more than one chronic illness. Subsequently, the worldwide predominance of diverse diseases is expected to grow as the geriatric population increases. This is regarded as a major driver for IVD market expansion.

Additionally, the global burden of chronic diseases like cardiovascular diseases (CVDs), diabetes, respiratory illness, and cancer has been increasing rapidly. In-vitro diagnostic tests will empower the early diagnosis and discovery of these illnesses by using biomarkers and detecting disorders advancement by physiological changes. The rise in chronic illness can be due to numerous components, mainly lifestyle-related, like unhealthy diet, use of tobacco, growing alcohol consumption, and inactive life.

In addition, as per the International Diabetes Federation's (IDF) latest report of November 2023, 537 million adults, i.e., 1 in every 10, were living with diabetes in 2021, with the number expected to rise to 643 million by 2030 and 783 million by 2045. 44% of adults stay undiagnosed, which is approximately 1 in 2, with the larger part having type 2 diabetes. Over 3 in 4 diabetes patients live in low and middle-income nations, and 541 million adults have a high chance of developing type 2 diabetes. Moreover, the rising focus of healthcare organizations and governments on preventative measures for controlling the increasing burden of chronic illness will additionally propel market growth in the predicted period.

In-Vitro Diagnostics Market Restraint:

• Unfavorable reimbursement can hinder the market growth.

Inadequate reimbursement is a substantial barrier to the IVD market development. A couple of years ago, Medicare in the US changed how it repaid several IVD tests, including molecular diagnostics. Few molecular pathology tests do not have their own claim Healthcare Common Procedure Coding System (HCPCS) codes, so they are charged utilizing unlisted codes instead. Medicare Administrative Contractors (MACs) set an installment sum for their local purviews on such occasions. These changes will likely harm the molecular and hereditary testing industry within the United States, constraining the IVD market's expansion.

In-Vitro Diagnostics Market Geographical Outlook:

• The North American region is expected to hold a substantial market share.

North America is anticipated to be the biggest market for in vitro diagnostics amid the projected period, and it is likely to continue to do so due to its well-developed healthcare framework and rising healthcare awareness among patients. Other components that contribute to the market's development include the availability of devices, expanded knowledge about their utilization, and the presence of many populations suffering from diverse chronic conditions. Another component driving the in vitro diagnostics market development is the presence of many major companies in North America. Moreover, due to an increase in healthcare expenditure, the rate of diabetes in the region is expected to increase at the highest rate throughout the projection period. Conceivable factors, such as the huge population of patients with other chronic illnesses that necessitate IVD testing, are fueling the regional market's expansion.

In-Vitro Diagnostics Market Key Developments:

• May 2023- Thermo Fisher Scientific and Pfizer agreed to expand local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries, including Latin America, Africa, the Middle East, and Asia. The collaboration aims to bring rapid NGS testing to decentralized labs closer to patients' treatment sites. Thermo Fisher works by detecting local labs by employing its NGS technology, ensuring they have the required infrastructure, trained workforce, and quality control measures. At the same time, Pfizer operates to provide affordable patient access to NGS tests and increase healthcare providers' awareness of innovative testing.
• May 2023- Siemens Healthineers introduced two high-volume hematology test systems, the Atellica Hema 570 Analyzer and the Atellica Hema 580 Analyzer, which clear out labor barriers in hematology testing. These analyzers execute complete blood counts (CBC), among the most performed diagnostic tests in laboratories. They provide connectivity, intuitive interfaces, automation, and integrated rules-based testing to interpret complex patient results efficiently. These solutions address the requirement for high-volume hematology testing and deliver critical data reliably.
• May 2023- Hologic Inc., a global leader in women's health, announced a collaboration with NFL cornerback Kelee Ringo, who was drafted recently, and his mother, Tralee Hale, a breast cancer survivor, to raise awareness among women about the importance of making yearly mammograms and other critical health screenings a priority.

In Vitro Diagnostics Market Scope:

Report Metric	Details
In Vitro Diagnostics Market Size in 2025	US$109.480 billion
In Vitro Diagnostics Market Size in 2030	US$145.459 billion
Growth Rate	CAGR of 5.87%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2025
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Technique Application End-User Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in In Vitro Diagnostics Market	Roche Diagnostics Plasmatec Vitro Bio Omega Diagnostics Group PLC & Technologien GmbH DST Diagnostische Systeme
Customization Scope	Free report customization with purchase

 

The Global In-Vitro Diagnostics market is segmented and analyzed as below:

• By Technique
  • Immunoassay
  • Molecular Diagnostics
  • Hematology
  • Others
• By Application
  • Infectious diseases
  • Autoimmune diseases
  • Drug Testing
  • Oncology
  • Others
• By End-User
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research Laboratories and Institutes
• By Geography
  • North America
    • United States
    • Canada              
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Taiwan
    • Thailand
    • Indonesia
    • Others

Our Best-Performing Industry Reports:

• Atherectomy Devices Market
• Drug Eluting Stent Market
• Disposable Flexible Duodenoscope Market

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS 

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNIQUE

5.1. Introduction

5.2. Immunoassay

5.3. Molecular Diagnostics

5.4. Hematology

5.5. Others

6. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION

6.1. Introduction

6.2. Infectious diseases

6.3. Autoimmune diseases

6.4. Drug Testing

6.5. Oncology

6.6. Others

7. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USER

7.1. Introduction

7.2. Diagnostic Laboratories

7.3. Hospitals and Clinics

7.4. Research Laboratories and Institutes

8. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Technique

8.2.2. By Application

8.2.3. By End User

8.2.4. By Country

8.2.4.1. United States

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Technique

8.3.2. By Application

8.3.3. By End User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Technique

8.4.2. By Application

8.4.3. By End User

8.4.4. By Country

8.4.4.1. Germany

8.4.4.2. France

8.4.4.3. United Kingdom

8.4.4.4. Italy

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Technique

8.5.2. By Application

8.5.3. By End User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Israel

8.5.4.4. Others

8.6. Asia Pacific

8.6.1. By Technique

8.6.2. By Application

8.6.3. By End User

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. South Korea

8.6.4.4. India

8.6.4.5. Australia

8.6.4.6. Taiwan

8.6.4.7. Thailand

8.6.4.8. Indonesia

8.6.4.9. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Roche Diagnostics

10.2. Plasmatec

10.3. Vitro Bio

10.4. Omega Diagnostics Group PLC & Technologien GmbH 

10.5. DST Diagnostische Systeme

10.6. SD Biosensor

10.7. Abbott Diagnostics

10.8. Meril Diagnostics

10.9. NIPPON GENE CO., LTD. 

10.10. Rapid Diagnostics Group of Companies

Roche Diagnostics

Plasmatec

Vitro Bio

Omega Diagnostics Group PLC & Technologien GmbH 

DST Diagnostische Systeme

SD Biosensor

Abbott Diagnostics

Meril Diagnostics

NIPPON GENE CO., LTD. 

Rapid Diagnostics Group of Companies